Skip to main content


Fig. 2 | BMC Infectious Diseases

Fig. 2

From: Simeprevir with pegylated interferon alfa 2a plus ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a meta-analysis and historical comparison

Fig. 2

Sustained virologic response in HCV-1/HIV coinfected patients treated with simeprevir + PegIFNα-2a + RBV (study C212) or PegIFNα-2a + RBV alone (random-effects meta-analysis of historical studies). CI = confidence interval; RBV = Ribavirin; SVR24 = sustained virologic response 24 weeks after planned end of treatment; w.a. = weight-adapted

Back to article page